Sanofi's next-gen hemophilia drugs take a PhIII bow — but can they still make their mark at this stage? - Endpoints News

Back in early 2018, when Sanofi put up $11.6 billion to buy Bioverativ and its hemophilia drugs Eloctate and Alprolix, the deal looked out of step to many. Roche had just scored a major win with an approval for Hemlibra, which quickly swelled into a blockbust…

Days after President Joe Biden signed an executive order directing HHS to expand access to birth control, HRA Pharma filed an application to become the first FDA-approved contraceptive pill available… [+704 chars]

full article...